Name:	knsa_ConsecutiveSuspensionOfActivitiesPeriodToTerminateAgreement
Namespace Prefix:	knsa_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Amount of future maximum contractual obligation for milestone payment upon the achievement of specified regulatory milestones.

No definition available.

Name:	knsa_ContractualObligationRegulatoryMilestoneFutureMaximumPayments
Namespace Prefix:	knsa_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Period from the agreement effective date after which the agreement can be terminated.

No definition available.

Name:	knsa_PeriodAfterWhichAgreementCanBeTerminated
Namespace Prefix:	knsa_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The amount of research and development expense related to purchase of drug materials.

No definition available.

Name:	knsa_ResearchAndDevelopmentExpenseRelatedToPurchaseOfDrugMaterials
Namespace Prefix:	knsa_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The notice period upon which the Company can terminate the agreement after eighteen months of agreement effective date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	knsa_TimePeriodToTerminateAgreementAfterEighteenMonthsOfAgreement
Namespace Prefix:	knsa_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The notice period to terminate the agreement after US marketing approval of the developed product, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	knsa_TimePeriodToTerminateAgreementAfterU.s.MarketingApprovalOfDevelopedProduct
Namespace Prefix:	knsa_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The period which both parties can terminate the agreement on uncured material breaches, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	knsa_TimePeriodToTerminateAgreementByBothPartiesUnderUncuredMaterialBreaches
Namespace Prefix:	knsa_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The notice period to terminate the agreement if products are having safety concerns, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	knsa_TimePeriodToTerminateAgreementIfProductsAreDeterminedToHaveCertainSafetyConcerns
Namespace Prefix:	knsa_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The period which the Company can terminate the agreement under payment-related, breaches in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	knsa_TimePeriodToTerminateAgreementUnderPaymentRelatedBreaches
Namespace Prefix:	knsa_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The cash outflows associated with upfront payment.

No definition available.

Name:	knsa_UpfrontPayment
Namespace Prefix:	knsa_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

No definition available.

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Name:	srt_CounterpartyNameAxis=knsa_RegeneronPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=knsa_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=knsa_ClinicalSupplyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: